KR102807716B1 - 산성 pH에서 증진된 활성을 갖는 항진균제 - Google Patents

산성 pH에서 증진된 활성을 갖는 항진균제 Download PDF

Info

Publication number
KR102807716B1
KR102807716B1 KR1020207005972A KR20207005972A KR102807716B1 KR 102807716 B1 KR102807716 B1 KR 102807716B1 KR 1020207005972 A KR1020207005972 A KR 1020207005972A KR 20207005972 A KR20207005972 A KR 20207005972A KR 102807716 B1 KR102807716 B1 KR 102807716B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
scy
pharmaceutically acceptable
mic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207005972A
Other languages
English (en)
Korean (ko)
Other versions
KR20200044823A (ko
Inventor
데이비드 에이. 안굴로 곤잘레스
Original Assignee
싸이넥시스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102807716(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 싸이넥시스, 인크. filed Critical 싸이넥시스, 인크.
Publication of KR20200044823A publication Critical patent/KR20200044823A/ko
Application granted granted Critical
Publication of KR102807716B1 publication Critical patent/KR102807716B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207005972A 2017-08-04 2018-07-31 산성 pH에서 증진된 활성을 갖는 항진균제 Active KR102807716B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541370P 2017-08-04 2017-08-04
US62/541,370 2017-08-04
PCT/US2018/044619 WO2019028034A1 (en) 2017-08-04 2018-07-31 Antifungal agents with enhanced activity in acidic ph

Publications (2)

Publication Number Publication Date
KR20200044823A KR20200044823A (ko) 2020-04-29
KR102807716B1 true KR102807716B1 (ko) 2025-05-13

Family

ID=63209698

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005972A Active KR102807716B1 (ko) 2017-08-04 2018-07-31 산성 pH에서 증진된 활성을 갖는 항진균제

Country Status (26)

Country Link
US (3) US11534433B2 (https=)
EP (3) EP4732902A2 (https=)
JP (1) JP7214714B2 (https=)
KR (1) KR102807716B1 (https=)
CN (2) CN111093655A (https=)
AU (2) AU2018309718B2 (https=)
BR (1) BR112020002290A2 (https=)
CA (1) CA3071940A1 (https=)
CY (1) CY1125690T1 (https=)
DK (1) DK3661503T3 (https=)
EA (1) EA202090445A1 (https=)
ES (1) ES2932658T3 (https=)
FI (1) FI3661503T3 (https=)
HR (1) HRP20221414T1 (https=)
HU (1) HUE060508T2 (https=)
LT (1) LT3661503T (https=)
MA (1) MA49751B1 (https=)
MD (1) MD3661503T2 (https=)
MX (1) MX2020001399A (https=)
PL (1) PL3661503T3 (https=)
PT (1) PT3661503T (https=)
RS (1) RS63746B1 (https=)
SI (1) SI3661503T1 (https=)
SM (1) SMT202200461T1 (https=)
TW (1) TWI805600B (https=)
WO (1) WO2019028034A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021016876A2 (pt) * 2019-02-27 2021-11-03 Scynexis Inc Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization
WO2022140646A1 (en) * 2020-12-26 2022-06-30 Mycovia Pharmaceuticals, Inc Dosing regimen for oteseconazole

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019203A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
HRP20220544T1 (hr) 2015-01-19 2022-08-05 Scynexis, Inc. Nove soli i polimorfi scy-078
MA49889A (fr) * 2017-04-10 2020-06-24 Scynexis Inc Agents antifongiques utilisés en association

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019203A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis" (2018.07.10.)*

Also Published As

Publication number Publication date
EP3661503B1 (en) 2022-09-07
BR112020002290A2 (pt) 2020-09-08
US20200390751A1 (en) 2020-12-17
EP4732902A2 (en) 2026-04-29
US20260000656A1 (en) 2026-01-01
JP2020529999A (ja) 2020-10-15
KR20200044823A (ko) 2020-04-29
MD3661503T2 (ro) 2023-01-31
HRP20221414T1 (hr) 2023-01-20
EA202090445A1 (ru) 2020-06-23
TW201919476A (zh) 2019-06-01
CA3071940A1 (en) 2019-02-07
FI3661503T3 (fi) 2022-12-15
HUE060508T2 (hu) 2023-03-28
AU2018309718B2 (en) 2024-07-25
MA49751B1 (fr) 2022-12-30
SMT202200461T1 (it) 2023-01-13
EP4169514B1 (en) 2026-01-28
US11534433B2 (en) 2022-12-27
ES2932658T3 (es) 2023-01-23
SI3661503T1 (sl) 2023-01-31
RS63746B1 (sr) 2022-12-30
CN118542868A (zh) 2024-08-27
CY1125690T1 (el) 2026-02-25
LT3661503T (lt) 2022-12-12
EP4169514A1 (en) 2023-04-26
PT3661503T (pt) 2022-12-13
PL3661503T3 (pl) 2023-01-09
EP3661503A1 (en) 2020-06-10
CN111093655A (zh) 2020-05-01
WO2019028034A1 (en) 2019-02-07
US20230364067A1 (en) 2023-11-16
MA49751A (fr) 2020-06-10
AU2024227501A1 (en) 2024-11-07
EP4169514C0 (en) 2026-01-28
MX2020001399A (es) 2020-08-06
JP7214714B2 (ja) 2023-01-30
TWI805600B (zh) 2023-06-21
AU2018309718A1 (en) 2020-02-27
DK3661503T3 (da) 2022-12-12

Similar Documents

Publication Publication Date Title
US20260000656A1 (en) Antifungal agents with enhanced activity in acidic ph
JP7574268B2 (ja) 併用される抗真菌剤
EP3917534B1 (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40091926A (en) Antifungal agents with enhanced activity in acidic ph
HK40030410B (en) Antifungal agents with enhanced activity in acidic ph
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph
TWI910099B (zh) 用於治療或預防肺囊蟲屬肺炎之三萜類抗真菌劑
HK40109129A (zh) 在酸性ph值下具有经增强活性的抗真菌剂
EA047126B1 (ru) Противогрибковое средство для лечения или профилактики инфекции вульвовагинального кандидоза
HK40062374A (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40062374B (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40022879B (en) Antifungal agents used in combination

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210729

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230817

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20240807

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250224

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250509

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250509

End annual number: 3

Start annual number: 1

PG1601 Publication of registration